Compare ULCC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | NNNN |
|---|---|---|
| Founded | 1994 | 2021 |
| Country | United States | Germany |
| Employees | 8198 | 27 |
| Industry | Air Freight/Delivery Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2017 | N/A |
| Metric | ULCC | NNNN |
|---|---|---|
| Price | $4.76 | $26.00 |
| Analyst Decision | Hold | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.21 | N/A |
| AVG Volume (30 Days) | ★ 6.9M | 11.4K |
| Earning Date | 05-05-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | N/A |
| Revenue This Year | $23.76 | N/A |
| Revenue Next Year | $11.48 | N/A |
| P/E Ratio | ★ N/A | $446.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.02 | $7.03 |
| 52 Week High | $6.66 | $55.65 |
| Indicator | ULCC | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 56.92 | 54.93 |
| Support Level | $4.69 | $26.31 |
| Resistance Level | $4.81 | $30.21 |
| Average True Range (ATR) | 0.33 | 2.24 |
| MACD | 0.04 | -0.27 |
| Stochastic Oscillator | 60.85 | 49.66 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).